Patents by Inventor Claire Y. H. Kinney

Claire Y. H. Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11344615
    Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 31, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Publication number: 20210290749
    Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.
    Type: Application
    Filed: July 6, 2017
    Publication date: September 23, 2021
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Publication number: 20200360505
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 19, 2020
    Inventors: Jill A. LIVENGOOD, Holli GIEBLER, Whitney BALDWIN, Hansi DEAN, Claire Y.H. KINNEY
  • Patent number: 10632185
    Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 28, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Publication number: 20190298818
    Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 3, 2019
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Patent number: 10428313
    Abstract: Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a C protein from West Nile virus (WNV), and a prM protein and an E protein from Dengue virus (DENV). The DENV may be DEN1 serotype, DEN2 serotype, DEN3 serotype, or DEN4 serotype. Also disclosed herein are compositions and methods for eliciting an immune response in a subject, such as an immune response to one or more DENV serotypes. In particular embodiments, the compositions include one or more inactivated viruses including a WN/DENV chimeric nucleic acid (such as a tetravalent inactivated vaccine including a WN/DEN1 chimera, a WN/DEN2 chimera, a WN/DEN3 chimera, and a WN/DEN4 chimera). The compositions may be administered to a subject to elicit an immune response.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 1, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Patent number: 10335478
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: July 2, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol University
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Publication number: 20170114330
    Abstract: Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a C protein from West Nile virus (WNV), and a prM protein and an E protein from Dengue virus (DENV). The DENV may be DEN1 serotype, DEN2 serotype, DEN3 serotype, or DEN4 serotype. Also disclosed herein are compositions and methods for eliciting an immune response in a subject, such as an immune response to one or more DENV serotypes. In particular embodiments, the compositions include one or more inactivated viruses including a WN/DENV chimeric nucleic acid (such as a tetravalent inactivated vaccine including a WN/DEN1 chimera, a WN/DEN2 chimera, a WN/DEN3 chimera, and a WN/DEN4 chimera). The compositions may be administered to a subject to elicit an immune response.
    Type: Application
    Filed: June 19, 2015
    Publication date: April 27, 2017
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Publication number: 20160367658
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Applicants: The Government of the USA, as represented by the Secretary, Department of Health and Human Services, Mahidol University
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Patent number: 9463233
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: October 11, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol University
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Patent number: 9169298
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: October 27, 2015
    Assignees: Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20150031857
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Application
    Filed: August 4, 2014
    Publication date: January 29, 2015
    Inventors: Richard KINNEY, Claire Y.H. Kinney, Veronique Barban, Jean Lang, Bruno Guy
  • Patent number: 8795688
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: August 5, 2014
    Assignees: Sanofi Pasteur, Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20140141040
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Patent number: 8715689
    Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: May 6, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Claire Y. H. Kinney, Eric Thomas Beck, Richard M. Kinney
  • Patent number: 8673316
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: March 18, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol University
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
  • Publication number: 20120083585
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Application
    Filed: October 25, 2011
    Publication date: April 5, 2012
    Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20120083584
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Application
    Filed: October 25, 2011
    Publication date: April 5, 2012
    Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20120014981
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: August 18, 2011
    Publication date: January 19, 2012
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
  • Patent number: 8067566
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: November 29, 2011
    Assignees: Sanofi Pasteur, Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy